EyePoint Pharmaceuticals (EYPT) Revenue & Revenue Breakdown
EyePoint Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$46.02M
Latest Revenue (Q)
$9.48M
Main Segment (Y)
Y U T I Q Product
Main Geography (Y)
UNITED STATES
EyePoint Pharmaceuticals Revenue by Period
EyePoint Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $46.02M | 11.14% |
| 2022-12-31 | $41.40M | 12.09% |
| 2021-12-31 | $36.94M | 7.27% |
| 2020-12-31 | $34.44M | 69.10% |
| 2019-12-31 | $20.36M | 587.77% |
| 2018-06-30 | $2.96M | -60.72% |
| 2017-06-30 | $7.54M | 365.37% |
| 2016-06-30 | $1.62M | -93.90% |
| 2015-06-30 | $26.57M | 664.90% |
| 2014-06-30 | $3.47M | 62.06% |
| 2013-06-30 | $2.14M | -39.22% |
| 2012-06-30 | $3.53M | -28.98% |
| 2011-06-30 | $4.96M | -78.46% |
| 2010-06-30 | $23.05M | 89.55% |
| 2009-06-30 | $12.16M | 249.88% |
| 2008-06-30 | $3.48M | 55.53% |
| 2007-06-30 | $2.23M | 52.52% |
| 2006-06-30 | $1.47M | 132.78% |
| 2005-06-30 | $629.52K | 137.35% |
| 2004-06-30 | $265.23K | 256.73% |
| 2003-06-30 | $74.35K | -85.60% |
| 2002-06-30 | $516.32K | - |
EyePoint Pharmaceuticals generated $46.02M in revenue during NA 2023, up 11.14% compared to the previous quarter, and up 1554.14% compared to the same period a year ago.
EyePoint Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $9.48M | -18.89% |
| 2024-03-31 | $11.68M | -16.71% |
| 2023-12-31 | $14.03M | -7.72% |
| 2023-09-30 | $15.20M | 66.96% |
| 2023-06-30 | $9.11M | 18.51% |
| 2023-03-31 | $7.68M | -27.06% |
| 2022-12-31 | $10.53M | 5.20% |
| 2022-09-30 | $10.01M | -13.43% |
| 2022-06-30 | $11.56M | 24.44% |
| 2022-03-31 | $9.29M | -19.49% |
| 2021-12-31 | $11.54M | 27.43% |
| 2021-09-30 | $9.06M | 0.51% |
| 2021-06-30 | $9.01M | 23.08% |
| 2021-03-31 | $7.32M | 2.69% |
| 2020-12-31 | $7.13M | -54.57% |
| 2020-09-30 | $15.70M | 280.76% |
| 2020-06-30 | $4.12M | -44.96% |
| 2020-03-31 | $7.49M | -13.25% |
| 2019-12-31 | $8.63M | 244.08% |
| 2019-09-30 | $2.51M | -65.20% |
| 2019-06-30 | $7.21M | 258.35% |
| 2019-03-31 | $2.01M | -17.61% |
| 2018-12-31 | $2.44M | 402.47% |
| 2018-09-30 | $486.00K | -32.03% |
| 2018-06-30 | $715.00K | -22.95% |
| 2018-03-31 | $928.00K | -0.54% |
| 2017-12-31 | $933.00K | 142.34% |
| 2017-09-30 | $385.00K | -45.08% |
| 2017-06-30 | $701.00K | 18.81% |
| 2017-03-31 | $590.00K | -90.12% |
| 2016-12-31 | $5.97M | 2055.60% |
| 2016-09-30 | $277.00K | -8.88% |
| 2016-06-30 | $304.00K | -6.17% |
| 2016-03-31 | $324.00K | -38.40% |
| 2015-12-31 | $526.00K | 12.88% |
| 2015-09-30 | $466.00K | 13.94% |
| 2015-06-30 | $409.00K | 24.70% |
| 2015-03-31 | $328.00K | -37.04% |
| 2014-12-31 | $521.00K | -97.94% |
| 2014-09-30 | $25.31M | 8566.78% |
| 2014-06-30 | $292.00K | -85.34% |
| 2014-03-31 | $1.99M | 236.49% |
| 2013-12-31 | $592.00K | -0.84% |
| 2013-09-30 | $597.00K | 21.34% |
| 2013-06-30 | $492.00K | -4.09% |
| 2013-03-31 | $513.00K | -12.31% |
| 2012-12-31 | $585.00K | 5.79% |
| 2012-09-30 | $553.00K | -20.89% |
| 2012-06-30 | $699.00K | 29.93% |
| 2012-03-31 | $538.00K | -14.60% |
| 2011-12-31 | $630.00K | -62.03% |
| 2011-09-30 | $1.66M | -55.34% |
| 2011-06-30 | $3.71M | 931.94% |
| 2011-03-31 | $360.00K | -13.04% |
| 2010-12-31 | $414.00K | -13.03% |
| 2010-09-30 | $476.00K | -96.97% |
| 2010-06-30 | $15.72M | 2952.82% |
| 2010-03-31 | $515.00K | -85.00% |
| 2009-12-31 | $3.43M | 1.48% |
| 2009-09-30 | $3.38M | 4.96% |
| 2009-06-30 | $3.22M | 1.90% |
| 2009-03-31 | $3.16M | 6.50% |
| 2008-12-31 | $2.97M | 5.84% |
| 2008-09-30 | $2.81M | 3.81% |
| 2008-06-30 | $2.70M | 398.71% |
| 2008-03-31 | $542.00K | - |
EyePoint Pharmaceuticals generated $9.48M in revenue during Q2 2024, up -18.89% compared to the previous quarter, and up 123.35% compared to the same period a year ago.
EyePoint Pharmaceuticals Revenue Breakdown
EyePoint Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|
| Y U T I Q Product | $28.33M | $16.96M | $13.88M | $12.05M |
| D E X Y C U Product | $11.58M | $18.35M | $6.95M | $4.78M |
EyePoint Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 22: Y U T I Q Product (70.99%), and D E X Y C U Product (29.01%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Sep 23 | Jun 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $1.07M | $816.00K | $5.27M | $11.19M | $8.59M | $8.74M | $6.68M | $5.76M | $3.71M | $6.71M | $543.00K | - | - | - | - | - | - | - | - |
| Y U T I Q Product | $1.10M | $9.02M | $7.27M | $7.42M | $4.61M | $5.83M | $3.93M | $4.17M | $3.03M | $3.96M | $3.47M | $2.88M | $4.74M | $55.00K | $6.71M | - | - | - | - |
| License And Collaboration Agreement | $7.78M | $14.14M | $3.60M | $202.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Royalty | $627.00K | $249.00K | $235.00K | $474.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Collaborative Research And Development | - | - | - | - | - | $15.00K | - | - | - | - | - | - | - | - | - | - | - | - | - |
| D E X Y C U Product | - | - | - | $833.00K | $2.45M | $3.90M | $4.40M | $5.35M | $4.66M | $4.57M | $3.77M | $2.72M | $2.29M | $827.00K | $3.14M | $954.00K | $684.00K | - | - |
EyePoint Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: License And Collaboration Agreement (73.57%), Y U T I Q Product (10.40%), Product (10.10%), and Royalty (5.93%).
EyePoint Pharmaceuticals Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Jun 18 |
|---|---|---|---|---|---|
| CHINA | $823.00K | $851.00K | $11.71M | $1.12M | - |
| UNITED STATES | $40.48M | $35.99M | $22.62M | $19.14M | $2.86M |
EyePoint Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 22: UNITED STATES (98.01%), and CHINA (1.99%).
Quarterly Revenue by Country
| Country | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D E X Y C U Product | $833.00K | $2.45M | $3.90M | $4.40M | $5.35M | $4.66M | $4.57M | $3.77M | $2.72M | $2.29M | $827.00K | $3.14M | $954.00K | $684.00K | - | - |
| License And Collaboration Agreement | $202.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Collaborative Research And Development | - | - | $15.00K | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Y U T I Q Product | $9.02M | $7.27M | $7.42M | $4.61M | $5.83M | $3.93M | $4.17M | $3.03M | $3.96M | $3.47M | $2.88M | $4.74M | $55.00K | $6.71M | - | - |
| Royalty | $474.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Product | - | - | - | - | $11.19M | $8.59M | $8.74M | $6.68M | $5.76M | $3.71M | $6.71M | $543.00K | - | - | - | - |
EyePoint Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Dec 22: Y U T I Q Product (85.67%), D E X Y C U Product (7.91%), Royalty (4.50%), and License And Collaboration Agreement (1.92%).
EyePoint Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| IPHA | Innate Pharma | $51.90M | $16.56M |
| EYPT | EyePoint Pharmaceuticals | $46.02M | $9.48M |
| HOOK | HOOKIPA Pharma | $20.13M | - |
| OCUP | Ocuphire Pharma | $19.05M | - |
| MREO | Mereo BioPharma Group | $10.00M | - |
| HCWB | HCW Biologics | $2.84M | $618.85K |
| OBIO | Orchestra BioMed | $2.76M | $778.00K |
| CMRX | Chimerix | $324.00K | $129.00K |
| ALXO | ALX Oncology | - | - |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| CABA | Cabaletta Bio | - | - |
| RVPH | Reviva Pharmaceuticals | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| ABOS | Acumen Pharmaceuticals | - | - |
| VIRX | Viracta Therapeutics | - | - |
| BMEA | Biomea Fusion | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| SLS | SELLAS Life Sciences Group | - | - |
EYPT Revenue FAQ
What is EyePoint Pharmaceuticals’s yearly revenue?
EyePoint Pharmaceuticals's yearly revenue for 2023 was $46.02M, representing an increase of 11.14% compared to 2022. The company's yearly revenue for 2022 was $41.4M, representing an increase of 12.09% compared to 2021. EYPT's yearly revenue for 2021 was $36.94M, representing an increase of 7.27% compared to 2020.
What is EyePoint Pharmaceuticals’s quarterly revenue?
EyePoint Pharmaceuticals's quarterly revenue for Q2 2024 was $9.48M, a -18.89% decrease from the previous quarter (Q1 2024), and a 4.09% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $11.68M, a -16.71% decrease from the previous quarter (Q4 2023), and a 52.08% increase year-over-year (Q1 2023). EYPT's quarterly revenue for Q4 2023 was $14.03M, a -7.72% decrease from the previous quarter (Q3 2023), and a 33.18% increase year-over-year (Q4 2022).
What is EyePoint Pharmaceuticals’s revenue growth rate?
EyePoint Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 24.58%, and for the last 5 years (2019-2023) was 125.97%.
What are EyePoint Pharmaceuticals’s revenue streams?
EyePoint Pharmaceuticals's revenue streams in c 22 are Y U T I Q Product, and D E X Y C U Product. Y U T I Q Product generated $28.33M in revenue, accounting 70.99% of the company's total revenue, up 67.04% year-over-year. D E X Y C U Product generated $11.58M in revenue, accounting 29.01% of the company's total revenue, down -36.93% year-over-year.
What is EyePoint Pharmaceuticals’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of EyePoint Pharmaceuticals was Y U T I Q Product. This segment made a revenue of $28.33M, representing 70.99% of the company's total revenue.